#LCSM

Joshua Bauml, MD

Jbauml

Next up @JSabari is presenting data on amivantamab in EGFR Exon20ins+ NSCLC. I have participated in the development of amivantamab, though I am not on this particular abstract. Excited to

Joshua Bauml, MD

Jbauml

Tonight at #WCLC20 we saw a RCT presented by Dr Lai on behalf of co-authors looking at immunotherapy in patients with EGFR+ NSCLC. Patients had disease that progressed on at

Joshua Bauml, MD

Jbauml

Up next I am going to go through the CodeBreaK100 trial, evaluating AMG510 in patients with KRAS G12C+ NSCLC. I know a lot of people have already gone over these

Stephen V Liu

StephenVLiu

#WCLC20 Passionate plea to clinical investigators designing clinical trials by @jillfeldman4 at the @IASLC plenary. Eloquent articulation at some of the fundamental flaws in our research infrastructure. This is a

Joshua Bauml, MD

Jbauml

The first abstract I want to talk about is a featured poster I am honored to present on behalf of my coauthors. FP14.06. This was a multicenter effort across North

Stephen V Liu

StephenVLiu

#WCLC20 The plenary presentation by @GoldmanLisa on patient-directed research and lessons in partnership is a can't miss and gives important insight into the evolution of clinical research #LCSM @IASLC @OncoAlert

Stephen V Liu

StephenVLiu

#OncoAlert Available @NEJM, results from the phase III CROWN trial of lorlatinib versus crizotinib as first line treatment for #ALK NSCLC. Initially presented at virtual #ESMO20, lorlatinib had a significantly

Stephen V Liu

StephenVLiu

#OncoAlert Retrospective report @JTOonline on outcomes with chemoradiation plus durvalumab (PACIFIC) in patients with #EGFR mutant NSCLC. #LCSM https://www.jto.org/article/S1556-0864(21)01702-0/fulltext Cohort of 37 patients with #EGFR muta

Stephen V Liu

StephenVLiu

#OncoAlert Results from the phase III TAHOE trial now available @JTOonline - compared 2L rovalpituzumab-teserine (Rova-T) versus topotecan in DLL3-high #SCLC. Stopped early for futility, not meeting its OS endpoint.

Arjun Gupta

guptaarjun90

1/ What are the benefit and harms of interventions to treat breathlessness (dyspnea) in people with advanced cancer?We explore non-pharmacologic interventions in @JAMAOnc #supponc #palloncA tweetorial...https://jamanetwork.com/journals/jama

Mike Thompson, MD, PhD, FASCO

mtmdphd

[THREAD] #ClinicalTrials Eligibility [Updated Mar 11, 2020] #ctsm Modernizing Eligibility Criteria for Molecularly Driven #ClinicalTrials [7/20/15] - @EdKimMDLCI et al. JCO @ASCO_pubs http://ow.ly/RGEdG metRCC Clinical Trial Participa

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.